Metraipolis › archive › dc_a2e580a28fe5
Preclinical screening models in anticancer drug development: strengths, limitations, and translational challenges — Europe PMC PMID:42199864
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42199864
- DOI
- 10.3389/fphar.2026.1822764
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T12:19:51.201Z
- SHA-256 of the archived text
22c81dc2009aed7670f19378cfd7c4a2c2d4351d47493c027356d72480a958f3- Stable URL of this page
https://metraipolis.com/documento/dc_a2e580a28fe5
How to cite
Preclinical screening models in anticancer drug development: strengths, limitations, and translational challenges — Europe PMC PMID:42199864 — Europe PMC (en), https://europepmc.org/article/MED/42199864 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a2e580a28fe5 (Metraipolis archive dc_a2e580a28fe5, sha256 22c81dc2009aed7670f19378cfd7c4a2c2d4351d47493c027356d72480a958f3)
BibTeX
@misc{dca2e580a28fe5,
title = {Preclinical screening models in anticancer drug development: strengths, limitations, and translational challenges — Europe PMC PMID:42199864},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42199864},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a2e580a28fe5; sha256 22c81dc2009aed7670f19378cfd7c4a2c2d4351d47493c027356d72480a958f3},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42199864. Agents can read the archived copy with the MCP tool read_document.